{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:47:54Z","timestamp":1759366074694,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T00:00:00Z","timestamp":1558137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.nefro.2019.02.013","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T08:46:15Z","timestamp":1560156375000},"page":"38-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efecto negativo del bloqueo del sistema renina-angiotensina sobre la progresi\u00f3n de la enfermedad renal cr\u00f3nica avanzada: \u00bfuna cuesti\u00f3n de ajuste de dosis?"],"prefix":"10.1016","volume":"40","author":[{"given":"Fernando","family":"Caravaca-Font\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juli\u00e1n","family":"Valladares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"D\u00edaz-Campillejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Luna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Caravaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2019.02.013_bib0160","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.02.013_bib0165","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1172\/JCI27699","article-title":"Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes","volume":"116","author":"Remuzzi","year":"2006","journal-title":"J Clin Invest."},{"key":"10.1016\/j.nefro.2019.02.013_bib0170","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ahj.2008.01.031","article-title":"Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis","volume":"155","author":"Balamuthusamy","year":"2008","journal-title":"Am Heart J."},{"key":"10.1016\/j.nefro.2019.02.013_bib0175","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1185\/030079908X291921","article-title":"Angiotensin receptor blockers: RAAS blockade and renoprotection","volume":"24","author":"Ruilope","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.nefro.2019.02.013_bib0180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3810\/pgm.2008.04.1758","article-title":"Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression","volume":"120","author":"Bakris","year":"2008","journal-title":"Postgrad Med."},{"key":"10.1016\/j.nefro.2019.02.013_bib0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.33549\/physiolres.933607","article-title":"The dilemma of dual renin-angiotensin system blockade in chronic kidney disease: why beneficial in animal experiments but not in the clinic?","volume":"66","author":"\u010cert\u00edkov\u00e1 Ch\u00e1bov\u00e1","year":"2017","journal-title":"Physiol Res."},{"key":"10.1016\/j.nefro.2019.02.013_bib0190","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2019.02.013_bib0195","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.clinthera.2007.09.019","article-title":"Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?","volume":"29","author":"Weir","year":"2007","journal-title":"Clin Ther."},{"key":"10.1016\/j.nefro.2019.02.013_bib0200","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1586\/erc.09.47","article-title":"Blocking the renin-angiotensin system: dual- versus mono-therapy","volume":"7","author":"Ravandi","year":"2009","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"10.1016\/j.nefro.2019.02.013_bib0205","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.02.013_bib0210","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1586\/erc.09.127","article-title":"Recent changes in the landscape of combination RAS blockade","volume":"7","author":"Epstein","year":"2009","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"10.1016\/j.nefro.2019.02.013_bib0215","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.02.013_bib0220","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.nefro.2019.02.013_bib0225","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2019.02.013_bib0230","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.ki.5000159","article-title":"ACE-inhibitor use and the long-term risk of renal failure in diabetes","volume":"69","author":"Suissa","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2019.02.013_bib0235","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2215\/CJN.02231205","article-title":"Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade","volume":"1","author":"Griffin","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2019.02.013_bib0240","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/08860220701742161","article-title":"Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors","volume":"30","author":"Onuigbo","year":"2008","journal-title":"Ren Fail."},{"key":"10.1016\/j.nefro.2019.02.013_bib0245","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11255-007-9299-2","article-title":"Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients","volume":"40","author":"Onuigbo","year":"2008","journal-title":"Int Urol Nephrol."},{"key":"10.1016\/j.nefro.2019.02.013_bib0250","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.02.013_bib0255","doi-asserted-by":"crossref","first-page":"c63","DOI":"10.1159\/000228536","article-title":"Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution","volume":"113","author":"Onuigbo","year":"2009","journal-title":"Nephron Clin Pract."},{"key":"10.1016\/j.nefro.2019.02.013_bib0260","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijcard.2017.03.080","article-title":"Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study","volume":"238","author":"Tseng","year":"2017","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.nefro.2019.02.013_bib0265","doi-asserted-by":"crossref","first-page":"e0170874","DOI":"10.1371\/journal.pone.0170874","article-title":"The impact of renin-angiotensin system blockade on renal outcomes and mortality in pre-dialysis patients with advanced chronic kidney disease","volume":"12","author":"Oh","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.nefro.2019.02.013_bib0270","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/ckj\/sfx083","article-title":"Patterns of progression of chronic kidney disease at later stages","volume":"11","author":"Caravaca-Font\u00e1n","year":"2018","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.nefro.2019.02.013_bib0275","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0272-6386(95)90657-6","article-title":"Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival","volume":"26","author":"Davies","year":"1995","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.nefro.2019.02.013_bib0280","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1373\/clinchem.2005.0525144","article-title":"Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program","volume":"52","author":"Myers","year":"2006","journal-title":"Clin Chem."},{"key":"10.1016\/j.nefro.2019.02.013_bib0285","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.nefro.2019.02.013_bib0290","first-page":"255","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial","volume":"31","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.02.013_bib0295","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.regpep.2012.03.002","article-title":"Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat","volume":"176","author":"Whaley-Connell","year":"2012","journal-title":"Regul Pept."},{"key":"10.1016\/j.nefro.2019.02.013_bib0300","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/HYPERTENSIONAHA.112.201889","article-title":"Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension","volume":"61","author":"Moniwa","year":"2013","journal-title":"Hypertension."},{"key":"10.1016\/j.nefro.2019.02.013_bib0305","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2165\/00003088-199324030-00005","article-title":"Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure","volume":"24","author":"Hoyer","year":"1993","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.nefro.2019.02.013_bib0310","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3317\/jraas.2002.046","article-title":"The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease","volume":"3","author":"Sica","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst."}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:54:40Z","timestamp":1759323280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699519300943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0211699519300943"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2019.02.013","relation":{},"ISSN":["0211-6995"],"issn-type":[{"type":"print","value":"0211-6995"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efecto negativo del bloqueo del sistema renina-angiotensina sobre la progresi\u00f3n de la enfermedad renal cr\u00f3nica avanzada: \u00bfuna cuesti\u00f3n de ajuste de dosis?","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2019.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}